Trial · NCT06276504
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Negativation of JCV viral load in the CSF as assessed by PCR: at least one JCV PCR in the CSF negative in the Day 0 to Month 3 period | At baseline (Day 0), 1 month, 2 months and 3 months | |
| Secondary | Negativation of JCV PCR viral load in the CSF: cumulative incidence of negative JCV viral load measures by PCR in CSF, with death as competing event | At baseline (Day 0), 1 month, 2 months and 3 months | |
| Secondary | Evolution of the JCV viral load in the CSF (repeated measures JCV PCR in CSF) | At baseline (Day 0), 1 month, 2 months and 3 months | |
| Secondary | Repositivation of JCV PCR: at least a positive result following at least a negative result | At baseline (Day 0), 1 month, 2 months and 3 months | |
| Secondary | Evolution of National Institutes of Health Stroke Scale (NIHSS) score | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | Repeated measures of neurological status |
| Secondary | Evolution of 6-item Modified Rankin Scale score (includes death as most severe state) | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | Repeated measures of degree of disability or dependence in the daily activities in neurological conditions |
| Secondary | Evolution of Glasgow Outcome Scale Extended (GOS-E) score | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | Repeated measures of neurological outcome and degree of disability in neurological conditions |
| Secondary | Relapse or progression | From baseline to end of participation, a maximum of 12 months | Adjudication by a dedicated committee ; based on clinical evolution, JCV PCR in CSF, brain MRI |
| Secondary | Death (and date of death) | From baseline to end of participation, a maximum of 12 months | |
| Secondary | Cause specific death: death related to PML | From baseline to end of participation, a maximum of 12 months | Adjudication by a dedicated committee |
| Secondary | Any adverse event classified by using US NCI CTCAE | From baseline to end of participation, a maximum of 12 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06276504/registered